Recently, the life science operating platform Scispot released its list of the Top 5 Zebrafish CROs in the World, with InVivo Biosystems at the top of the list! We are delighted to be recognized in this way and to represent the zebrafish community in the USA; and we congratulate all the other zebrafish CRO companies around the world.
It is encouraging to see the wide adoption of zebrafish in research, particularly pertaining to the drug development research that Scispot focuses on. Drug development is near and dear to us at InVivo Biosystems - we offer compound testing to better understand how they target biological functions, drug screens that can aid in drug repurposing for rare diseases, and humanized models of diseases which can act as ‘Clinical Avatars’.
Our partnerships have produced some exciting successes, such as the drug repurposing campaign to treat the congenital disorder PMM2-CDG in a little girl, Maggie. InVivo Biosystems created a precise model of the disorder, and working closely with the biotech Perlara, the drug Epalrestat was found to show significant improvements in Maggie’s stability, strength and motor skills. A 30-patient clinical trial (ages 2-17) began in Spring of 2021.
To read more about our work, and the current state of disease research check out some of our recent blogs: